Streetbeat News

Equity Actions

EDBL

Edible Garden announced a reverse stock split of its common stock at a ratio of 1-for-20, effective 12:01 a.m. ET, April 5, 2024. Post-split trading on Nasdaq under symbol 'EDBL' begins April 5, 2024.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 8:33 pm

PLAY

Dave & Buster's Entertainment Inc (NASDAQ:PLAY) reported Q4 earnings of $1.03 per share, missing the consensus estimate of $1.10, and quarterly sales of $599.1 million, slightly below the estimate of $602.609 million. Comparable store sales decreased 7% year-over-year but increased 8% compared to 2019. The company repurchased 8.5 million shares for $300 million and increased its share repurchase authorization by $100 million to $200 million. CEO Chris Morris highlighted the opening of six new stores, a new international agreement, growth in Adjusted EBITDA margins, and a strong foundation for future growth.

Portfolio Pulse from Erica Kollmann

April 02, 2024 | 8:31 pm

DINO

HF Sinclair has agreed to repurchase 5 million shares of its outstanding common stock from a selling stockholder, as disclosed in an 8-K filing.

Portfolio Pulse from Charles Gross

April 02, 2024 | 8:25 pm

RNA

Avidity Biosciences has filed a prospectus for the proposed resale or other disposition by selling securityholders of up to 15.2 million shares of common stock. Additionally, the prospectus covers up to 9 million shares issuable upon the exercise of pre-funded warrants.

Portfolio Pulse from Charles Gross

April 02, 2024 | 8:24 pm

ONMD

OneMedNet has entered into a securities purchase agreement as of March 28, which will provide the company with up to $4.54 million in funding. This financial injection comes through a private placement of senior convertible notes.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 8:12 pm

ADPT

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) announced a strategic review update, preliminary Q1 2024 revenue of $41M-$43M, exceeding estimates of $38.21M, and a CFO transition. The review concluded with a decision to operate the MRD and Immune Medicine businesses internally with increased independence and dedicated resources. MRD revenue for Q1 2024 is expected to be $31M-$32M, a 47% increase from Q1 2023. Tycho Peterson will depart as CFO, succeeded by Kyle Piskel.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 8:12 pm

ONMD

OneMedNet announces that Aaron Green, previously President, has now taken on the additional roles of CEO and board member following the retirement of former CEO Paul Casey. Casey will continue to serve on the Board of Directors.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 8:10 pm

LUNG

Pulmonx Corporation (NASDAQ:LUNG) announced the appointment of Mehul Joshi as Chief Financial Officer, effective April 3, 2024. Joshi, with over 30 years of experience in finance and strategic planning, succeeds John McKune. His background includes roles at Gilead Sciences, ResMed Inc., and PhenomeX Inc., highlighting his capability to lead global finance teams and contribute to Pulmonx's growth strategies.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 8:09 pm

INTC

Intel has introduced a new financial reporting structure aligned with its Foundry operating model for 2024 and beyond. The company provided recast financial results for 2023, 2022, and 2021, outlining a path for long-term growth and profitability of Intel Foundry. The new structure aims at improving financial performance and increasing shareholder value.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 8:06 pm

ROK

Recent analyst ratings for Rockwell Automation (NYSE:ROK) show a mix of perspectives, with a shift towards a more bearish outlook in the last 30 days. The average 12-month price target has been adjusted to $284.89, a decrease from the previous $306.88. Analysts from firms like Barclays, JP Morgan, and Citigroup have updated their ratings and price targets, reflecting changes in market conditions and company performance. Rockwell Automation's financial indicators such as market capitalization, revenue growth, net margin, ROE, and ROA remain strong, though debt management poses a challenge.

Portfolio Pulse from Benzinga Insights

April 02, 2024 | 8:01 pm